Stoke is pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. We develop antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney. We believe our proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, will allow us to deliver disease-modifying therapies in a highly precise, durable and controlled manner. Source
No articles found.
We enable cheaper, faster, and better genetic engineering of plants. We offer our ...
We enable cheaper, faster, and better genetic e...
SI-BONE is a medical device company that has pioneered a proprietary minimally inv...
SI-BONE is a medical device company that has pi...
Ascendis Pharma is applying its innovative technology platform to build a leading,...
Ascendis Pharma is applying its innovative tech...
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...
Atara Biotherapeutics is a leading off-the-shel...
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology comp...
Amicus Therapeutics (Nasdaq: FOLD) is a global,...
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing...
Axsome Therapeutics, Inc. is a clinical-stage b...
We are a biotechnology company focused on delivering transformational therapies fo...
We are a biotechnology company focused on deliv...
Join the National Investor Network and get the latest information with your interests in mind.